B Hauer1, L Fiebig, B Brodhun, W Haas. 1. 1Department for Infectious Disease Epidemiology, Respiratory Infections Unit, Robert Koch Institute Postfach 65 02 61, D-13302 Berlin +49-30-18-754-3328 +49-30-18-754-3341 HauerB@rki.de Germany.
Abstract
BACKGROUND: In 2007, the 'Berlin Declaration on Tuberculosis' (BD) was signed by the Ministers of the WHO European Region Member States (MS) to address the re-emerging threat of tuberculosis (TB) by fully implementing the Stop TB strategy. WHO Euro developed a Monitoring and Evaluation (M&E) Framework using programmatic and epidemiological indicators to follow-up the BD from 2013 onwards. Ahead of this, we explored the Framework performance for Germany, a low TB incidence country. METHODS: We selected from a surveillance perspective on five country-specific indicators asked for all MS. Information sources included guidelines, notification data and laboratory quality assurance results. RESULTS: As to national TB guidelines (indicator 1.1.1), up-to-date guidance documents are available. Regarding external quality assurance (3.2) proficiency testing confirms high quality of culture and drug-susceptibility testing. M/XDR-TB prevention and control is reflected by a 1.7% MDR-TB rate in 2010 with decreasing tendency (4.1.2). As to treatment success (5), the WHO target of 85% is reached for all age groups except the elderly ≥60 years. Germany disposes of an electronic case-based surveillance providing evidence for TB policy and practices (5.2.2). CONCLUSIONS: The selected M&E Framework indicators proved well applicable to a low-incidence country. The results show no specific gaps in TB surveillance and control in Germany.
BACKGROUND: In 2007, the 'Berlin Declaration on Tuberculosis' (BD) was signed by the Ministers of the WHO European Region Member States (MS) to address the re-emerging threat of tuberculosis (TB) by fully implementing the Stop TB strategy. WHO Euro developed a Monitoring and Evaluation (M&E) Framework using programmatic and epidemiological indicators to follow-up the BD from 2013 onwards. Ahead of this, we explored the Framework performance for Germany, a low TB incidence country. METHODS: We selected from a surveillance perspective on five country-specific indicators asked for all MS. Information sources included guidelines, notification data and laboratory quality assurance results. RESULTS: As to national TB guidelines (indicator 1.1.1), up-to-date guidance documents are available. Regarding external quality assurance (3.2) proficiency testing confirms high quality of culture and drug-susceptibility testing. M/XDR-TB prevention and control is reflected by a 1.7% MDR-TB rate in 2010 with decreasing tendency (4.1.2). As to treatment success (5), the WHO target of 85% is reached for all age groups except the elderly ≥60 years. Germany disposes of an electronic case-based surveillance providing evidence for TB policy and practices (5.2.2). CONCLUSIONS: The selected M&E Framework indicators proved well applicable to a low-incidence country. The results show no specific gaps in TB surveillance and control in Germany.
Entities:
Keywords:
tuberculosis, Berlin Declaration (BD), monitoring, evaluation, framework, Germany
Authors: R Diel; G Loytved; A Nienhaus; S Castell; A Detjen; H Geerdes-Fenge; W Haas; B Hauer; B Königstein; D Maffei; K Magdorf; M Priwitzer; J-P Zellweger; R Loddenkemper Journal: Pneumologie Date: 2011-05-10
Authors: R Ziegler; H-M Just; S Castell; R Diel; P Gastmeier; W Haas; B Hauer; G Loytved; M Mielke; I Moser; A Nienhaus; E Richter; H Rüden; S Rüsch-Gerdes; T Schaberg; N Wischnewski; R Loddenkemper Journal: Pneumologie Date: 2012-01-31
Authors: T Schaberg; T Bauer; S Castell; K Dalhoff; A Detjen; R Diel; U Greinert; B Hauer; C Lange; K Magdorf; R Loddenkemper Journal: Pneumologie Date: 2012-02-10
Authors: Gérard Krause; Doris Altmann; Daniel Faensen; Klaudia Porten; Justus Benzler; Thomas Pfoch; Andrea Ammon; Michael H Kramer; Hermann Claus Journal: Emerg Infect Dis Date: 2007-10 Impact factor: 6.883